GoAI
Get started
ABVC BioPharma, Inc. logo

ABVC BioPharma, Inc.

ABVC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.8899

−$0.01 · -1.11%

Aug 21, 4:00 PM ET

ABVC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

46

Neutral

Sentiment

51

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Uttam Yashwant Patil
Listed since
Nov 10, 2004
Employees
18

Market position

Day range

Current $0.8899

52-week range

Current $0.8899

Open
$0.92
Previous close
$0.8999
Volume
56.79K
0.45× average
Average volume
125.35K
Average daily volume
Market cap
23.14M USD
Beta
0.54
Market reference 1
50-day average
$1.2447
-28.51% below average
200-day average
$1.6134
-44.84% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
52.33M USD
P/E (TTM)
-3.02×
P/B (TTM)
2.25×
P/S (TTM)
-29.07×
EV / EBITDA
-7.04×
Earnings yield
-15.97%
Free cash flow yield
-6.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
918.55%
Net margin
992.85%
Return on equity
-71.17%
Return on assets
-37.55%
Return on invested capital
-42.64%

Financial health

Debt / equity
0.17×
Current ratio
0.41×
Altman Z-score
-5.53
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends621%-1463%-3547%-5630%Gross margin, FY2021: 98.57%Gross margin, FY2022: 70.47%Gross margin, FY2023: -98.15%Gross margin, FY2024: 99.85%Operating margin, FY2021: -3290.07%Operating margin, FY2022: -1558.54%Operating margin, FY2023: -4439.24%Operating margin, FY2024: -923.34%Net margin, FY2021: -3608.47%Net margin, FY2022: -1693.50%Net margin, FY2023: -5109.26%Net margin, FY2024: -962.12%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 98.57%. Gross margin FY2022 70.47%. Gross margin FY2023 -98.15%. Gross margin FY2024 99.85%. Operating margin FY2021 -3290.07%. Operating margin FY2022 -1558.54%. Operating margin FY2023 -4439.24%. Operating margin FY2024 -923.34%. Net margin FY2021 -3608.47%. Net margin FY2022 -1693.50%. Net margin FY2023 -5109.26%. Net margin FY2024 -962.12%.

Income trends

Revenue

509.59K USD+234.31%

Operating income

−7.15M USD-51.98%

Net income

−7.91M USD-61.30%
Income trends across reported periods2.71M USD−4.25M USD−11.21M USD−18.16M USDRevenue, FY2021: 355.8K USDRevenue, FY2022: 969.78K USDRevenue, FY2023: 152.43K USDRevenue, FY2024: 509.59K USDOperating income, FY2021: −11.71M USDOperating income, FY2022: −15.11M USDOperating income, FY2023: −6.77M USDOperating income, FY2024: −4.71M USDOperating income, FY2025: −7.15M USDNet income, FY2021: −12.84M USDNet income, FY2022: −16.42M USDNet income, FY2023: −7.79M USDNet income, FY2024: −4.9M USDNet income, FY2025: −7.91M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 355.8K USD. Revenue FY2022 969.78K USD. Revenue FY2023 152.43K USD. Revenue FY2024 509.59K USD. Operating income FY2021 −11.71M USD. Operating income FY2022 −15.11M USD. Operating income FY2023 −6.77M USD. Operating income FY2024 −4.71M USD. Operating income FY2025 −7.15M USD. Net income FY2021 −12.84M USD. Net income FY2022 −16.42M USD. Net income FY2023 −7.79M USD. Net income FY2024 −4.9M USD. Net income FY2025 −7.91M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—509.59K USD152.43K USD969.78K USD355.8K USD
Cost of goods sold—763 USD302.04K USD286.42K USD5.09K USD
Gross profit—508.83K USD−149.61K USD683.37K USD350.71K USD
Research and development121.09K USD179.27K USD1.06M USD2.69M USD1M USD
Selling, general, and administrative7.03M USD5.03M USD5.55M USD13.1M USD11.05M USD
Operating expenses7.15M USD5.21M USD6.62M USD15.8M USD12.06M USD
Interest income167.1K USD87.36K USD185.48K USD187.82K USD43.2K USD
Interest expense415.89K USD825.9K USD1.31M USD293.97K USD227.21K USD
Depreciation and amortization504.83K USD200.92K USD380.39K USD23.8K USD11.99K USD
Operating income−7.15M USD−4.71M USD−6.77M USD−15.11M USD−11.71M USD
Net income−7.91M USD−4.9M USD−7.79M USD−16.42M USD−12.84M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
8 beats, 0 misses, 0 met estimates
Average EPS surprise
+86.16%
8 comparable reports
Latest EPS result
-0.03
Estimate -0.4 · Beat by 92.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.16-0.43-1.03-1.62Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26No estimateQ2 '26No estimateQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 0.017, estimate -1.5, surprise +101.15%, Beat. Q2 2025, reported Apr 30, 2025: actual 0.04, estimate -0.5, surprise +108.00%, Beat. Q3 2025, reported Aug 13, 2025: actual -0.13, estimate -0.6, surprise +78.33%, Beat. Q4 2025, reported Oct 31, 2025: actual -0.05, estimate -0.4, surprise +87.50%, Beat. Q1 2026, reported Mar 3, 2026: actual -0.12, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 18, 2026: actual -0.06, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual -0.03, estimate -0.4, surprise +92.50%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -0.4, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates484.09K25.81K-432.48K-890.77KQ4 '24BeatQ1 '25MissQ2 '25EstimateQ3 '25EstimateQ4 '25EstimateQ1 '26No estimateQ3 '26EstimateQ4 '26Estimate
Q4 2024, reported Nov 14, 2024: actual 389.28K USD, estimate 26.18K USD, surprise +1387.15%, Beat. Q1 2025, reported Mar 11, 2025: actual 1.97K USD, estimate 26.44K USD, surprise -92.56%, Miss. Q2 2025, reported Apr 30, 2025: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 13, 2025: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q4 2025, reported Oct 31, 2025: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 3, 2026: actual -795.95K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual —, estimate 113.26K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 16, 2026: actual —, estimate 113.26K USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jul 25, 2023

1:10

Stock split

Effective May 8, 2019

1:18

Stock split

Effective Apr 11, 2016

157:50

Stock split

Effective Aug 13, 2015

1:5,000

Stock split

Effective Feb 18, 2011

1:5

Stock split

Effective Jun 19, 2007

1,573:1,000

ABVC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ABVC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
364.48K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
210.36K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research ABVC

research.disclaimer